EUVIMEDEUVIMED entdecken
VergleichsstudieKohortenstudieOpen Access · CC BY 4.0

Comparable real‐world effectiveness between switches to cabotegravir + rilpivirine long‐acting or modern daily oral regimens in the United States: an OPERA cohort study

Ricky K Hsu, Michael G Sension, Jennifer S Fusco, Laurence Brunet, Quateka Cochran, Brooke Levis, Gayathri Sridhar, Vani Vannappagari, Jean Van Wyk, Michael B Wohlfeiler, Gregory P Fusco

Journal of the International AIDS Society · 2025

DOI: 10.1002/jia2.70068 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of the International AIDS Society, 2025. Verfasst von Ricky K Hsu und 10 weiteren Autor:innen. Beteiligte Einrichtung: AIDS Healthcare Foundation, New York, New York, USA. Hauptthemen laut MEDLINE: Rilpivirine, HIV Infections, Anti-HIV Agents, Pyridones. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction Cabotegravir + rilpivirine long‐acting (CAB+RPV LA) injectable was approved in the United States in 2021 for HIV‐1 treatment in virologically suppressed (viral load [VL]

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RilpivirineHIV InfectionsAnti-HIV AgentsPyridonesHumansMaleFemaleAdultUnited StatesMiddle AgedAdministration, OralViral LoadCohort StudiesHIV-1Diketopiperazines

Stichwörter der Autor:innen

HIVcabotegravirlong‐acting injectablepersistencereal‐world evidencerilpivirinevirologic suppression

Substanzen

RilpivirinecabotegravirAnti-HIV AgentsPyridonesDiketopiperazines

Autor:innen und Institutionen

  • AIDS Healthcare Foundation, New York, New York, USA.
  • NYU Langone Health, New York, New York, USA.
  • CAN Community Health, Fort Lauderdale, Florida, USA.
  • Epividian, Raleigh, North Carolina, USA.
  • AIDS Healthcare Foundation, Fort Lauderdale, Florida, USA.
  • ViiV Healthcare, Durham, North Carolina, USA.

Zitieren

APA

Hsu, R. K., Sension, M. G., Fusco, J. S., Brunet, L., Cochran, Q., Levis, B., Sridhar, G., Vannappagari, V., Wyk, J. V., Wohlfeiler, M. B., & Fusco, G. P. (2025). Comparable real‐world effectiveness between switches to cabotegravir + rilpivirine long‐acting or modern daily oral regimens in the United States: an OPERA cohort study. Journal of the International AIDS Society. https://doi.org/10.1002/jia2.70068

Vancouver

Hsu RK, Sension MG, Fusco JS, Brunet L, Cochran Q, Levis B, et al. Comparable real‐world effectiveness between switches to cabotegravir + rilpivirine long‐acting or modern daily oral regimens in the United States: an OPERA cohort study. Journal of the International AIDS Society. 2025. doi:10.1002/jia2.70068

BibTeX
@article{Hsu2025,
  author = {Hsu, Ricky K and Sension, Michael G and Fusco, Jennifer S and Brunet, Laurence and Cochran, Quateka and Levis, Brooke and Sridhar, Gayathri and Vannappagari, Vani and Wyk, Jean Van and Wohlfeiler, Michael B and Fusco, Gregory P},
  title = {Comparable real‐world effectiveness between switches to cabotegravir + rilpivirine long‐acting or modern daily oral regimens in the United States: an OPERA cohort study},
  journal = {Journal of the International AIDS Society},
  year = {2025},
  doi = {10.1002/jia2.70068}
}
Kostenlos starten →